Livionex, recently announced a successful end-of-Phase 2 meeting with the FDA, supporting the advancement of C-KAD, a 2.6% EDTA ophthalmic solution, to a Phase 3 clinical study. In an interview with ...
Autism is a complex interplay of symptoms that extend far beyond the diagnostic labels commonly associated with mental health conditions. From mood dysregulation and attentional challenges to trauma ...